2,3,4,5-tetrahydroxypentanal has been researched along with Heart Failure in 1 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibarrola, J | 1 |
| Matilla, L | 1 |
| Martínez-Martínez, E | 1 |
| Gueret, A | 1 |
| Fernández-Celis, A | 1 |
| Henry, JP | 1 |
| Nicol, L | 1 |
| Jaisser, F | 1 |
| Mulder, P | 1 |
| Ouvrard-Pascaud, A | 1 |
| López-Andrés, N | 1 |
1 other study available for 2,3,4,5-tetrahydroxypentanal and Heart Failure
| Article | Year |
|---|---|
Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition.
Topics: Animals; Biomarkers; Blood Proteins; Disease Models, Animal; Galectin 3; Galectins; Gene Expression; | 2019 |